This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Alert me on articles by topic

The Therapeutic Dilemma of Idiopathic Monosymptomatic Demyelinating Syndromes

Arch Neurol. 2000;57:930-932.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

IDENTIFYING EFFECTIVE treatments that alter the disease process in multiple sclerosis (MS) has been a 150-year odyssey involving all corners of the earth. On the subject of treatment for MS, Charcot¹ in 1877 stated that " . . . the time has not yet come when such a subject can be seriously considered." Until very recently, this still held true.

Recognition that the disease process in MS was related to perturbations in immune system activity led to the assessment of anti-inflammatory and immunosuppressant therapeutic strategies. The elucidation of networks that regulate immune system activity has yielded new immunotherapeutic approaches. Furthermore, details of the disease process in MS have been identified that will facilitate the design of targeted therapies with greater specificity and effectiveness.

Natural history studies have shown that within 15 years after disease onset, 50% of patients reach an EDSS (Expanded Disability Status Scale) score of 6.0 and require . . . [Full Text of this Article]

RELATED ARTICLE

Multiple Sclerosis—From Probable to Definite Diagnosis: A 7-Year Prospective Study
Anat Achiron and Yoram Barak
Arch Neurol. 2000;57(7):974-979.
ABSTRACT | FULL TEXT